NexLife Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.3/10
Best for: coaching inside the $145/month rather than sold separately
NexLife falls below our bar on oversight: the FDA has issued it a warning letter. Read the breakdown below before you give it money.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
charged as a multi-month plan up front
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
In the price
Prices checked August 2026
Compounded semaglutide starts at $145/mo and compounded tirzepatide at $186/mo. NexLife runs a telehealth platform, is LegitScript-certified, and says it works only with pharmacies that are LegitScript-certified and NABP-accredited.
Is NexLife legit?
NexLife is a real, operating US company, and the FDA has issued it a warning letter. The letter is summarized at the top of this review. Read what it alleges before you decide, and raise it with the clinician who would prescribe for you. We rate NexLife 7.3/10 overall.
Is there a NexLife promo or coupon code?
We know of no promo or coupon code for NexLife. Its listed price is $145 a month. Coupon sites advertising "NexLife discount codes" are not a source we can vouch for, and any genuine offer shows at checkout without a code.
See how NexLife compares on our rankings of the best semaglutide providers and the best tirzepatide providers.
Vetted alternatives to NexLife
Trimi Health
Best for: knowing which pharmacy fills the vial: it names VialsRx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
NexLife at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $145/mo
- Pricing model
- Flat: the price stays the same as the dose goes up
- What's included
- Medication · Consult · Shipping · Coaching
- FDA status
- 1 FDA warning letter (details below)
How NexLife scores
Six columns, each one computed from something NexLife has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
7.1/10$186/month is 26% below the $250 median for compounded tirzepatide across the sellers we compare. That figure is a multi-month plan paid up front, not a month-to-month rate, so the comparison flatters it.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
7.5/10A price is shown before the questionnaire starts. A live video visit is required, which is slower but the more careful intake.
Trust & Safety15%
3.5/10The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. It shows a price before asking for health information.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
8.5/10The price covers the medication, clinician visits, shipping and coaching.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on NexLife
Last checked August 2026- Checked the listed price across 4 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for NexLife
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
What signing up with NexLife involves
What to expect on the way to a prescription: where the price appears, who fills the medication, and what the monthly price covers. It is not medical advice, and a clinician makes the prescribing decision.
- 1NexLife shows a price on its own site before asking anything about you, so you can compare it with other sellers before you start a questionnaire.
- 2The intake requires a live video visit with a clinician before a first prescription, which takes longer than a written form and is the more careful route.
- 3Ask NexLife which pharmacy fills the prescription before you pay. The pharmacy's name is what lets you check its license.
- 4The monthly price includes the medication, clinician visits, shipping and coaching.
- Lowest ongoing monthly price: semaglutide $145, tirzepatide $186. That leaves out membership fees, first-month rates and insurance copays.
- Confirm that NexLife serves your state before you start.
- The FDA has issued NexLife a warning letter. It is covered in the enforcement section below; read what it alleges before you decide.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Contacting NexLife
- Phone
- +1 (949) 818-8000
- NexLife offers email support
GLP-1 medications NexLife offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Plan ladder: $165 monthly, $149/mo 3-mo, $147/mo 6-mo, $145/mo 12-mo. $145 is the 12-month-plan rate, not a promo.
Plan ladder: $215 monthly, $195/mo 3-mo, $190/mo 6-mo, $186/mo 12-mo. $186 is the 12-month-plan rate, not a promo.
Check the price yourself before you pay
Every figure here was read off NexLife's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide costs $145 a month, 22% below the $185 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $186 a month, 26% below the $250 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price stays the same as your dose goes up
- The monthly price includes the medication, clinician visits, shipping and coaching
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued NexLife a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What NexLife charges
NexLife charges $145/month, and holds that rate across every dose. Flat dose pricing matters more than it sounds: on a tiered plan the bill grows with the dose, so the figure that got you to sign up is not the one you end up paying.
- Compounded semaglutide: $165/month
- Compounded semaglutide: $145/month
- Compounded tirzepatide: $215/month
- Compounded tirzepatide: $186/month
For compounded tirzepatide, the median across the sellers we compare is $250/month, so NexLife's $186 is genuinely below the middle, not just advertised that way.
Found, at about $149/month, is the closest like-for-like alternative we review.
What NexLife dispenses
NexLife prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product: the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
Safety and disclosure
NexLife tells you its price before you start the medical questionnaire and that its pharmacy is accredited. It also offers coaching as part of the plan. The FDA has issued NexLife a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. Because the medication is compounded, the most useful question to ask at intake is which licensed pharmacy fills the prescription. If NexLife will not tell you, treat that as a warning sign. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Everything listed here is compounded.
- You need insurance to cover the cost. Check whether NexLife bills your plan before you start.
- A seller's regulatory history matters to you more than price. Read the warning letter summarized above before deciding.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
- you want coaching bundled in rather than billed on top
Our read
NexLife competes on price, and at $186/month for compounded tirzepatide it competes well. The FDA warning letter is what to weigh against that, not a footnote to it. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
NexLife falls below our bar on oversight: the FDA has issued it a warning letter. Read the breakdown below before you give it money.
Before you pay NexLife
Starting at $145 a month. Check today's price, then start the intake.
Where NexLife is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these two counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider Sesame Care.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo).
Compare NexLife head to head
The sellers closest to NexLife on medication and price.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
NexLife has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this NexLife review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See NexLife's current pricing
Plans start at $145 a month. Whether you qualify is a clinician's decision, made after your intake.